Loading market dashboard
AtriCure, Inc.
ATRCHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested.
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AtriCure (ATRC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. “Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined execution and increased adoption of our innovative products,” said Michael Carrel, President and Chief Executive Officer.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Bank of America Securities Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, May 12, 2026, at 10:00 a.m. Pacific Daylight Time. Interested par.
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to discuss its first quarter financial results. Those interested in listening to th.
ArtiCure Chief Science Officer sold 5,000 shares for a transaction value of approximately $149,000 at around $29.83 per share on March 12, 2026. The sale represented 4.91% of Vinayak's direct holdings, reducing direct ownership from 101,875 to 96,875 shares.
Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company.
Citigroup Inc. raised its position in AtriCure, Inc. (NASDAQ: ATRC) by 182.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,085 shares of the medical device company's stock after purchasing an additional 36,839 shares during the period. Citigroup
